Prophylactic tranexamic acid for reducing blood loss in pregnant females undergoing cesarean section: A systematic review and meta‐analysis
Journal of Obstetrics and Gynaecology Research · 2024-09 · 50 (9) · 1439-1458
DOI: 10.1111/jog.16036 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Obstetrics and Gynaecology Research, online erschienen am 31.07.2024. Verfasst von Ammar Al Naimi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Buergerhospital, Frankfurt, Germany. Hauptthemen laut MEDLINE: Antifibrinolytic Agents, Blood Loss, Surgical, Cesarean Section, Tranexamic Acid. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
We aim to assess the efficacy of prophylactic tranexamic acid (TXA) in reducing blood loss after cesarean section (CS).
Methods
We systematically searched PubMed and Embase for randomized controlled trials published between 1990 and 2023 to conduct a meta‐analysis on adult women undergoing CS and receiving prophylactic TXA.
Results
Twenty‐four trials, comprising 19 584 participants, were included. Most studies included women with healthy, full‐term, singleton pregnancies. The pooled estimate showed a reduction in mean blood loss in the TXA arm with a standardized mean difference (SMD) of −1.50 (−2.03, −0.98: p < 0.001). There was a high level of heterogeneity ( I 2 98.86%). A subgroup analysis demonstrated no statistical difference in the effect of TXA on blood loss at 2 h of follow‐up with SMD of −2.24 (−3.23, −1.35) compared to −1.07 (−1.56, −0.58) and −1.10 (−2.62, −0.42) at 24 and 48 h, respectively ( p = 0.11). The effect of TXA on blood loss was smaller in high‐income countries with SMD −0.24 (−0.44, −0.04) ( I 2 63%) than in low‐/middle‐income countries −1.78 (−2.35, −1.21) with I 2 98%. Only three studies had low risk of bias and the effect of TXA from two of them was SMD −0.31 (−0.54, −0.09) ( I 2 0%).
Conclusions
Despite the apparent beneficial effect of TXA in reducing blood loss after CS for women with uncomplicated term pregnancies, heterogeneity remains a serious concern. The current body of knowledge consists predominantly of small, likely biased studies, and large unbiased studies show only limited effects of prophylactic TXA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, Buergerhospital, Frankfurt, Germany.
- Department of Obstetrics and Perinatal Medicine, Goethe University Hospital of Frankfurt, Frankfurt, Germany.
- Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
- Department of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
- Department of Internal Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.
ORCID-Profile: Ammar Al Naimi
Zitieren
APA
Al Naimi, A., Ma, H., Pearl, A., Yungtum, G., & Rangasamy, V. (2024). Prophylactic tranexamic acid for reducing blood loss in pregnant females undergoing cesarean section: A systematic review and meta‐analysis. Journal of Obstetrics and Gynaecology Research, 50(9), 1439-1458. https://doi.org/10.1111/jog.16036
Vancouver
Al Naimi A, Ma H, Pearl A, Yungtum G, Rangasamy V. Prophylactic tranexamic acid for reducing blood loss in pregnant females undergoing cesarean section: A systematic review and meta‐analysis. Journal of Obstetrics and Gynaecology Research. 2024;50(9):1439-1458. doi:10.1111/jog.16036
BibTeX
@article{AlNaimi2024,
author = {Al Naimi, Ammar and Ma, Haobo and Pearl, Abarna and Yungtum, Greg and Rangasamy, Valluvan},
title = {Prophylactic tranexamic acid for reducing blood loss in pregnant females undergoing cesarean section: A systematic review and meta‐analysis},
journal = {Journal of Obstetrics and Gynaecology Research},
year = {2024},
volume = {50},
number = {9},
pages = {1439--1458},
doi = {10.1111/jog.16036}
}
EUVIMED